Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Obstructive lung disease Stories

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-12-17 08:29:39

--Last patient dosed in moderate asthma trial and first patient dosed in COPD study-- QUEBEC CITY, Dec. 17, 2013 /PRNewswire/ -- Asmacure Ltee today announced that the company has completed dosing in a Phase 2 trial evaluating its lead compound, ASM-024, in moderate asthma patients, with data anticipated in the first quarter of 2014. The company also has begun patient enrollment in a Phase 2 trial of ASM-024 in patients with moderate and severe chronic obstructive pulmonary disease...

Yoga Can Help Patients With COPD Improve Lung Function
2013-10-29 06:18:51

April Flowers for redOrbit.com - Your Universe Online A new study from researchers at the All India Institute of Medical Sciences, Department of Pulmonary Medicine and Sleep Disorders reveals that patients with COPD can improve their lung function by practicing yoga. The study found that lung function, shortness of breath and inflammation all demonstrated significant improvement after patients completed 12 weeks of yoga training. The study results were presented at CHEST 2013, the...

2013-10-28 12:26:16

Apollo(TM) 2.0 Released Enhancing Clinical Experience CHICAGO, Oct. 28, 2013 /PRNewswire/ -- VIDA Diagnostics, a leading provider of quantitative imaging and informatics services to aid diagnosis and treatment planning for patients with pulmonary disease, announces the release of Apollo 2.0, here at the 2013 American College of Chest Physicians (Chest) Conference. The software advance signifies the next generation product expansion of their flagship Apollo® pulmonary imaging...

2013-09-09 08:28:07

DORVAL, QC, Sept. 9, 2013 /CNW/ - Novartis announced new analyses of data for investigational QVA149 (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed clinically significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus those comparators evaluated in the study(1,2).( )These data were part of 39...

2013-09-08 20:20:26

Phase 3 results presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 RIDGEFIELD, Conn., Sept. 8, 2013 /PRNewswire/ -- Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 mcg delivered once daily via the Respimat(®) inhaler provided improvements in lung function in patients with moderate to very severe...

2013-09-03 08:27:37

DORVAL, QC, Sept. 3, 2013 /CNW/ - Ontario patients suffering from chronic obstructive pulmonary disease (COPD) now have access to SEEBRI* BREEZHALER* (glycopyrronium bromide) 50 mcg with its listing as a General Benefit on the Ontario Drug Benefit (ODB) Formulary. SEEBRI* BREEZHALER* is available in pharmacies province-wide. SEEBRI* BREEZHALER* is a long-acting anticholinergic (LAAC) indicated for long-term, once-daily maintenance bronchodilator treatment in patients with COPD,...

2013-08-27 08:27:23

SAN DIEGO, Aug. 27, 2013 /PRNewswire/ -- Carolus Therapeutics, Inc. and The Alpha-1 Project, Inc. (TAP), a wholly-owned subsidiary of the Alpha-1 Foundation, today announced that they are collaborating to characterize human biological samples for the presence of the novel target, RANTES:PF4 heterodimer (the heteromer), a soluble protein complex that is secreted by activated platelets and implicated in many inflammation-related diseases, including genetic emphysema and COPD...

2013-06-12 10:54:43

Simultaneously elevated levels of the biomarkers C-reactive protein, fibrinogen and leukocyte count in individuals with chronic obstructive pulmonary disease (COPD) were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations, according to a study in the June 12 issue of JAMA. "Exacerbations of respiratory symptoms in COPD are of major importance because of their profound and long-lasting adverse effects on...

Almost Half Of COPD Diagnoses Are Wrong
2013-05-22 12:56:06

Peter Suciu for redOrbit.com — Your Universe Online A new study has found that chronic obstructive pulmonary disease (COPD) is over-diagnosed among uninsured patients. Researchers found that over 40 percent of patients being treated for COPD at federally funded clinics did not actually have the disease. COPD is a progressive lung disease that leads to the loss of lung function and is primarily caused by smoking. The disease causes coughing, wheezing, shortness of breath, chest...